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patient. Compared to symptomatic therapy, patient with AR treated with allergen
immunotherapy obtained approx. 0.75 month (3 years of vaccination followed by
5-year evaluation) and 3.45 month (4-year follow up including 3 years of vaccina-
tion) without AB. The QALY for costs has been calculated between 8516 € - 8883 €.
CONCLUSIONS: In the Slovak Republic, Staloral allergen immunotherapy of aller-
gic rhinitis is effective from the clinical as well as pharmacoeconomic point of
view.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) poses a significant
burden on health care budgets. The impact of impaired and lost productivity is less
known. The aim of this study was to explore the economic burden of COPD in
patients of working age in The Netherlands across three areas: health care utiliza-
tion, impaired productivity and lost productivity resulting from early retirement
due to COPD. METHODS: Dutch direct medical costs were derived from a literature
review and applied to individual COPD patients. Costs of productivity impairment
due to COPD were estimated from the ‘COPD uncovered’ survey, adopted for The
Netherlands. Costs due to lost productivity due to early retirement were based on
a cohort of COPD patients of working age followed in a Markov model for 20 years
until (early) retirement or death. The costing year was 2011. RESULTS: The annual
health care costs for patients with COPD aged 45-64 years in The Netherlands were
estimated at around €70 million. The annual impaired productivity costs were €120
million. Lost productivity due to early retirement were estimated at around €510
million per year; the majority of €350 million for men and €160 million for women.
These lost productivity costs represented 21% of the productivity that may have
been generated by COPD patients if they had not retired early. CONCLUSIONS: The
‘COPD UNCOVERED’ model was used to estimate the economic burden of COPD in
The Netherlands. Costs due to impaired and lost productivity in COPD patients of
working age was considerable and several times higher than the medical cost of
COPD. Young working population provide a main target for interventions aimed to
improve COPD disease management.
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OBJECTIVES: According to the GOLD report (2011), COPD is associated with signif-
icant economic burden. For Ukraine as for developing country, the human capital
(employed economically active population) is the most important national asset
and COPD-related work-place loss may represent a serious threat for Ukrainian
economics. METHODS: Via the best fit (least square) linear regression forecast we
modeled the 2012-2020 dynamics of the key socioeconomic and COPD-related ep-
idemiological indicators for general Ukrainian population and employed econom-
ically active population. Modeling was based on the 2005-2011 reports of the Ukrai-
nian National Center of Statistics and data from WHO. Using forecasting results the
number of new COPD cases and COPD-related deaths 2012-2020 was calculated.
Also we calculated and compared 2012 and 2020 direct and indirect costs.
RESULTS: According to the forecasting results, number of total Ukrainian popula-
tion and employed economically active population could amount 45453100 and
20393267, respectively, in 2012 and 43484907 and 20845448, respectively, in 2020.
Number of COPD patients in 2012 and 2020 could be 1766748 and 1731332, respec-
tively, in general population and 792680 and 829952, respectively, in employed
economically active population. Number of 2012-2020 new COPD cases and COPD
related deaths could be 1230750 and 56207, respectively, in general population and
570737 and 25892, respectively, in employed economically active population. We
estimated that in 2012 direct COPD costs could be 87,17% greater than indirect
COPD costs and could amount to €326367598 vs. €193607579,9, respectively. In 2020
indirect COPD costs could 1,47% exceed the direct costs and could amount
€496997427,8 vs. 489796409, respectively. CONCLUSIONS: Results of modeling
show that socioeconomic burden of COPD will be significant for Ukraine during the
2012-2020 periods. COPD costs will rise with the significant growth of indirect costs,
which may be typically for Ukraine as for developing country.
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OBJECTIVES: Asthma, a major chronic respiratory disease, has become a cause of
global concern in terms of its increasing prevalence, morbidity and economic im-
pact.Our aim was to examine the availability, pricing and affordability of asthma
medicines in Tehran. METHODS: The study methodology was designed using the
recommendations developed by the World Health Organization and Health Action
International on measuring medicine prices, availability, affordability and price
components. Data was collected from 5 public sector facilities and 10 private sector
retail pharmacies in the pilot study in 22 regions of Tehran.Data on price of inno-
vator brands (IBs) and lowest priced generics (LPGs) found at each facility were
gathered and applied for data analtysis. RESULTS: Generic beclomethasone was
found in 3 public sectors and generic salbutamol was available in 4 public sec-
tors.The availability of IB beclomethasone was poor in all of the regions surveyed
.IB beclomethasone was available at 2 out of 5 and 5 out of 10 pharmacies surveyed
in public and private sectors, respectively. The availability of generic beclometha-
sone inhalers was 90%. IB salbutamol inhalers were available in all the surveyed
regions.At the time of the survey, the lowest paid unskilled government worker
earned 108 400 Iranian Rials (IRR) (US$ 11.78) per day. CONCLUSIONS: The poor
availability of inhalers at public facilities affects those patients who depend on
these facilities for treatment and medications. In the past decade, some barriers
were imposed by the Ministry of Health on registering certain pharmaceuticals . A
new approach has focused on reducing these barriers and there is a need for stron-
ger government action to introduce or improve national medicine policy as well as
effective pricing policies.
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OBJECTIVES: To systematically identify economic evaluations of treatments rec-
ommended for chronic idiopathic urticaria (CIU) and studies reporting health-state
utility weights and/or estimates of resource use and costs. METHODS: Systematic
searches of MEDLINE, MEDLINE-In-Process, EconLit, EMBASE, the Cochrane Li-
brary, and conference abstracts were conducted from 1 January 2000 to 20 Decem-
ber 2011. Inclusion criteria considered studies reporting utility weights, resource
use, costs, and/or economic evaluations of treatments in CIU patients older than 12
years. RESULTS: From 266 retrieved records, 3 studies were included: 1 economic
evaluation of levocetirizine and 2 cost studies. The economic evaluation was a
pooled analysis of two clinical trials comparing levocetirizine with placebo and
incorporating productivity losses defined as absenteeism and/or presenteeism.
One cost study reported total annual per-patient direct costs of $1,762; the other
study reported a cost range between $1,290 and $2,419, depending on disease se-
verity. Cost components included prescriptions, visits, hospitalisations, and labo-
ratory costs. Annual per-patient indirect costs, defined as disease-related loss of
earnings, were between $213 and $484, depending on severity. Although no utility
studies in CIU were found, one study demonstrated that CIU severely impairs
health-related quality of life at the same level as skin conditions, such as psoriasis
and atopic dermatitis, on certain dimensions. CONCLUSIONS: This review identi-
fied limited evidence on costs, only one economic evaluation, and no utility data for
CIU. Lacking comparative data, it is impossible to conclude what the most cost-
effective treatment in CIU might be. Due to discrepancies between the cost studies,
it is difficult to conclude which cost component contributed the most; however,
one study reported that productivity loss was a major component. This review
highlighted the substantial cost burden and a humanistic burden, comparable to
other skin disorders, of CIU. Further research in this area is needed.
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OBJECTIVES: According to the GOLD report (2011) COPD is associated with signifi-
cant economic burden. COPD exacerbations account for the greatest proportion of
the total COPD costs. Frequency and severity of COPD exacerbation could be re-
duced by the appropriate medication that could be reimbursed by Ukrainian
Government.METHODS:To determine the net benefit ratio we assessed total COPD
costs and the COPD exacerbation-related costs reduction as benefit (effectiveness)
for tiotropium (18 mcg daily) and salmeterol (50 mcg two times a day) compared to
usual COPD treatment practice of GPs. Direct costs included medication costs,
outpatient and inpatient costs. Indirect costs included productivity loss and tem-
porary disability related payments. Calculations were performed per 1000 em-
ployed economically active COPD patients. The data about the outpatient visits and
hospitalizations was received from results of Ukrainian retrospective study (for
usual practice regimen) and from the POET study results (for tiotropium and sal-
meterol). Prices for medical services were received from appropriate survey (2011)
and were counted with May 2011-May 2012 inflation index and salary growth rates.
The minimal market medication prices (on 15 June 2012) were included in calcula-
tions. Sensitivity analysis was conducted with medication price decrease.
RESULTS: Results show that total COPD costs per 1000 employed economically
active COPD patients in 2012 could amount €498052,34, €441697,07 and €508983,73
with usual COPD treatment practice of GPs, salmeterol and tiotropium, respec-
tively. Reduction of exacerbation-related COPD costs compared to usual practice
could amount €85698,78 for salmeterol and €114380,78 for tiotropium. Cost benefit
ratio for salmeterol could be 5,15 and for tiotropium could be 4,45. In case of 27%
price drop salmeterol could be more beneficial than tiotropium. CONCLUSIONS:
According to results of the cost-benefit analysis tiotropium is more beneficial for
COPD basis in employed economically active Ukrainian population than salmeterol
compared to usual practice. It could be reimbursed by Ukrainian government.
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